Three reasons the Administration should abandon its International Pricing Index proposal

According to the Council of Economic Advisers, “Heavy-handed government intervention may reduce drug prices in the short term, but these savings are not worth the long-term cost of American patients...
Read More
Drug importation: An old idea that is still a bad idea

2020 may have kicked off a new decade, but policymakers are stuck in the past, focusing on old, dangerous ideas like drug importation. For all the same reasons we’ve discussed before, drug...
Read More
Cancer medicines cost twice as much at hospitals, study finds

Cancer medicines cost nearly twice as much in hospital outpatient facilities than in physician offices in the commercial market, according to a new study from the Employee Benefit Research Institute...
Read More
ICYMI: 2019 brings innovative medicines to patients

New reports from the U.S. Food and Drug Administration (FDA) show a total of 55 novel new medicines were approved in 2019. Among these, 48 were approved by the Center for Drug Evaluation and Research...
Read More
New GAO report: Some hospitals participating in 340B may not be eligible for the program

The Government Accountability Office (GAO) released a new report on 340B hospital eligibility compliance and made a number of alarming observations that underscore the need for more accountability in...
Read More
Nearly 50% of brand medicine spending goes to the supply chain and others

Nearly 50% of total spending on brand medicines – the sum of all payments made at the pharmacy or paid on a claim to a health care provider – went to the supply chain and other entities in 2018,...
Read More
ICYMI: Cancer death rate declines at record levels thanks to innovative medicines

Each year, the American Cancer Society estimates the number of new cancer cases and deaths that will occur in the United States. For nearly 30 years, the trend towards fewer cancer deaths has been...
Read More